DRREDDY
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Updates with Amgen's investment plan
Sept 26 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.
However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Updates with Amgen's investment plan
Sept 26 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.
However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Dr. Reddy’s Laboratories Signs Agreement to Supply Affordable Lenacapavir for HIV Prevention in 120 Low- and Middle-Income Countries
Dr. Reddy's Laboratories Limited has announced a new agreement, brokered by CHAI and Unitaid, to develop and supply affordable, quality-assured generic versions of lenacapavir for HIV prevention in low- and middle-income countries. Under the agreement, Dr. Reddy's will receive financial, technical, and regulatory support to deliver the product by 2027, following regulatory approval. The injectable lenacapavir regimen will be priced at US$40 per person per year, with the required initial oral course available for no more than US$17. This initiative is part of a broader multi-partner, multi-supplier strategy to expand access to long-acting HIV prevention medicines. Dr. Reddy's is among the first generic suppliers to enter the market, following voluntary licenses granted by Gilead to six generic manufacturers in October 2024. The agreement aims to increase competition, ensure supply reliability, and support global efforts to prevent HIV.
Dr. Reddy's Laboratories Limited has announced a new agreement, brokered by CHAI and Unitaid, to develop and supply affordable, quality-assured generic versions of lenacapavir for HIV prevention in low- and middle-income countries. Under the agreement, Dr. Reddy's will receive financial, technical, and regulatory support to deliver the product by 2027, following regulatory approval. The injectable lenacapavir regimen will be priced at US$40 per person per year, with the required initial oral course available for no more than US$17. This initiative is part of a broader multi-partner, multi-supplier strategy to expand access to long-acting HIV prevention medicines. Dr. Reddy's is among the first generic suppliers to enter the market, following voluntary licenses granted by Gilead to six generic manufacturers in October 2024. The agreement aims to increase competition, ensure supply reliability, and support global efforts to prevent HIV.
Indian drugmakers Dr Reddy's, Hetero to sell generic HIV prevention drug for $40 a year
Dr Reddy's, Hetero among six Indian companies with licensing deal from Gilead Sciences
Global health groups like Unitaid, Gates working with generic manufacturers to lower prices, broaden access
Experts say twice-a-year injection could help end AIDS crisis
Concerns remain not all countries will get affordable access
By Rishika Sadam and Jennifer Rigby
Sept 24 (Reuters) - Indian drugmakers Dr Reddy's Laboratories REDY.NS and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly effective HIV prevention drug for roughly $40 per year beginning in 2027.
Lenacapavir, developed by Gilead Sciences GILD.O and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly injection that was nearly 100% effective at preventing HIV in large trials.
Some AIDS experts, including activists and doctors, say it could help control the 44-year-long epidemic that still infects 1.3 million people a year, and which the World Health Organization estimates has killed 44 million.
ENABLING BROADER ACCESS
The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated U.S. price of around $28,000 a year for branded Yeztugo.
Unitaid, a WHO-hosted global health agency that works on bringing new tools and medicines to countries more cheaply, is providing technical and financial support to Dr Reddy's for the low-cost effort, alongside the Clinton Health Access Initiative and South Africa's Wits Reproductive Health and HIV Institute (Wits RHI), part of University of the Witwatersrand.
The Gates Foundation is working with Hetero.
"Generic manufacture of lenacapavir is essential to ensure this breakthrough HIV prevention option is not limited to a privileged few," said Professor Saiqa Mullick, director of implementation science at Wits RHI.
The generic version with its low price point could be a preferred choice by millions affected in low-income countries, Mullick said.
The two manufacturers are among six Gilead granted royalty-free licenses to last year, to produce and sell the drug in 120 low- and lower-middle income countries with the highest global HIV disease burden by 2027, subject to approvals.
"The ($40) price that we have negotiated... brings the product in parity with the cost of the oral PrEP," Carmen Perez Casas, Unitaid's strategic lead for HIV, told Reuters, using the short phrase for pre-exposure prophylaxis, or preventive, drugs.
Injections at six-month intervals could benefit people for whom stigma, logistics, and other barriers make it difficult to take a pill every day, she added.
CHEAP GENERICS NEEDED FOR LONG-TERM DEMAND
U.S. biotech Gilead has faced criticism from patient advocacy groups and activists for not including upper-middle- income countries such as those in Latin America in the generics agreement.
"We are supporting organizations and countries to reflect on how we could overcome those access barriers (in excluded nations)," Casas said, noting that some countries, including Brazil, took part in trials of the medication but could not access the generics as the agreement with Gilead stands.
Gilead is already working with the Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government to get doses of its branded drug at a reduced price to 2 million people starting this year while generics ramp up production.
But experts estimate that long-term demand is likely to be closer to 10 million people or more, highlighting the need for cheaper generics at scale.
"The availability of generics at an affordable price... will magnify the impact of this game-changing innovation," Peter Sands, chief executive of the Global Fund, told Reuters.
($1 = 88.6930 Indian rupees)
(Reporting by Rishika Sadam in Bengaluru and Jennifer Rigby in New York; Editing by Bill Berkrot)
(([email protected];))
Dr Reddy's, Hetero among six Indian companies with licensing deal from Gilead Sciences
Global health groups like Unitaid, Gates working with generic manufacturers to lower prices, broaden access
Experts say twice-a-year injection could help end AIDS crisis
Concerns remain not all countries will get affordable access
By Rishika Sadam and Jennifer Rigby
Sept 24 (Reuters) - Indian drugmakers Dr Reddy's Laboratories REDY.NS and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly effective HIV prevention drug for roughly $40 per year beginning in 2027.
Lenacapavir, developed by Gilead Sciences GILD.O and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly injection that was nearly 100% effective at preventing HIV in large trials.
Some AIDS experts, including activists and doctors, say it could help control the 44-year-long epidemic that still infects 1.3 million people a year, and which the World Health Organization estimates has killed 44 million.
ENABLING BROADER ACCESS
The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated U.S. price of around $28,000 a year for branded Yeztugo.
Unitaid, a WHO-hosted global health agency that works on bringing new tools and medicines to countries more cheaply, is providing technical and financial support to Dr Reddy's for the low-cost effort, alongside the Clinton Health Access Initiative and South Africa's Wits Reproductive Health and HIV Institute (Wits RHI), part of University of the Witwatersrand.
The Gates Foundation is working with Hetero.
"Generic manufacture of lenacapavir is essential to ensure this breakthrough HIV prevention option is not limited to a privileged few," said Professor Saiqa Mullick, director of implementation science at Wits RHI.
The generic version with its low price point could be a preferred choice by millions affected in low-income countries, Mullick said.
The two manufacturers are among six Gilead granted royalty-free licenses to last year, to produce and sell the drug in 120 low- and lower-middle income countries with the highest global HIV disease burden by 2027, subject to approvals.
"The ($40) price that we have negotiated... brings the product in parity with the cost of the oral PrEP," Carmen Perez Casas, Unitaid's strategic lead for HIV, told Reuters, using the short phrase for pre-exposure prophylaxis, or preventive, drugs.
Injections at six-month intervals could benefit people for whom stigma, logistics, and other barriers make it difficult to take a pill every day, she added.
CHEAP GENERICS NEEDED FOR LONG-TERM DEMAND
U.S. biotech Gilead has faced criticism from patient advocacy groups and activists for not including upper-middle- income countries such as those in Latin America in the generics agreement.
"We are supporting organizations and countries to reflect on how we could overcome those access barriers (in excluded nations)," Casas said, noting that some countries, including Brazil, took part in trials of the medication but could not access the generics as the agreement with Gilead stands.
Gilead is already working with the Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government to get doses of its branded drug at a reduced price to 2 million people starting this year while generics ramp up production.
But experts estimate that long-term demand is likely to be closer to 10 million people or more, highlighting the need for cheaper generics at scale.
"The availability of generics at an affordable price... will magnify the impact of this game-changing innovation," Peter Sands, chief executive of the Global Fund, told Reuters.
($1 = 88.6930 Indian rupees)
(Reporting by Rishika Sadam in Bengaluru and Jennifer Rigby in New York; Editing by Bill Berkrot)
(([email protected];))
Dr. Reddy's Laboratories Receives Positive CHMP Opinion for AVT03, a Biosimilar of Prolia® and Xgeva®, Pending European Commission Review
Dr. Reddy's Laboratories Limited has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® (denosumab) and Xgeva® (denosumab), in European markets. This development is part of the established approval process, and the CHMP's positive opinion will now be reviewed by the European Commission (EC) for a final decision on granting marketing authorization in the European Economic Area (EEA), which includes EU member countries, Norway, Iceland, and Liechtenstein. A separate Marketing Authorization Application (MAA) will be submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) under the International Recognition Procedure (IRP). The commercialization of AVT03 is a collaborative effort between Dr. Reddy's and Alvotech, with Dr. Reddy's holding exclusive rights for the U.S. market and semi-exclusive rights for Europe and the UK.
Dr. Reddy's Laboratories Limited has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® (denosumab) and Xgeva® (denosumab), in European markets. This development is part of the established approval process, and the CHMP's positive opinion will now be reviewed by the European Commission (EC) for a final decision on granting marketing authorization in the European Economic Area (EEA), which includes EU member countries, Norway, Iceland, and Liechtenstein. A separate Marketing Authorization Application (MAA) will be submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) under the International Recognition Procedure (IRP). The commercialization of AVT03 is a collaborative effort between Dr. Reddy's and Alvotech, with Dr. Reddy's holding exclusive rights for the U.S. market and semi-exclusive rights for Europe and the UK.
Dr Reddy's Laboratories Receives Positive CHMP Opinion For Avt03 Biosimilar
Sept 22 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
DR REDDY'S LABORATORIES LTD - RECEIVES POSITIVE CHMP OPINION FOR AVT03 BIOSIMILAR
DR REDDY'S LABORATORIES LTD - HAS EXCLUSIVE U.S. RIGHTS FOR AVT03
Source text: ID:nBSE9Yk6hw
Further company coverage: REDY.NS
(([email protected];))
Sept 22 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
DR REDDY'S LABORATORIES LTD - RECEIVES POSITIVE CHMP OPINION FOR AVT03 BIOSIMILAR
DR REDDY'S LABORATORIES LTD - HAS EXCLUSIVE U.S. RIGHTS FOR AVT03
Source text: ID:nBSE9Yk6hw
Further company coverage: REDY.NS
(([email protected];))
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Updates with GSK's investment plan
Sept 17 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.
However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Updates with GSK's investment plan
Sept 17 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.
However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Dr Reddy's Laboratories Launches Novel Molecule 'Tegoprazan' In India
Sept 16 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
LAUNCHES NOVEL MOLECULE 'TEGOPRAZAN' IN INDIA
Further company coverage: REDY.NS
(([email protected];;))
Sept 16 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
LAUNCHES NOVEL MOLECULE 'TEGOPRAZAN' IN INDIA
Further company coverage: REDY.NS
(([email protected];;))
Dr. Reddy's Laboratories Acquires STUGERON® Portfolio from Janssen Pharmaceutica for $50.5 Million to Expand CNS Portfolio
Dr. Reddy's Laboratories Limited has announced a definitive agreement to acquire the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. The acquisition includes the leading local brands Stugeron® FORTE and Stugeron® PLUS, along with related assets, across 18 markets in the Asia-Pacific and Europe, Middle East, and Africa regions, with India and Vietnam as key markets. The transaction, valued at USD 50.5 million, aims to bolster Dr. Reddy's Central Nervous System Portfolio, particularly in the anti-vertigo segment. The operations of the acquired portfolio will be gradually transitioned to ensure a smooth integration into Dr. Reddy's existing business.
Dr. Reddy's Laboratories Limited has announced a definitive agreement to acquire the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. The acquisition includes the leading local brands Stugeron® FORTE and Stugeron® PLUS, along with related assets, across 18 markets in the Asia-Pacific and Europe, Middle East, and Africa regions, with India and Vietnam as key markets. The transaction, valued at USD 50.5 million, aims to bolster Dr. Reddy's Central Nervous System Portfolio, particularly in the anti-vertigo segment. The operations of the acquired portfolio will be gradually transitioned to ensure a smooth integration into Dr. Reddy's existing business.
Dr. Reddy's Laboratories Receives Form 483 with 7 Observations from USFDA Following Inspection at UK Facility
Dr. Reddy's Laboratories Limited Discloses 2025 Penalty Order from GST Authority
Dr. Reddy's Laboratories Limited has received an order from the Joint Commissioner of Customs in Ludhiana, Punjab, imposing a penalty of Rs. 3 crore. The penalty is related to the alleged irregular availing of export incentives by the company under the Customs Act, 1962. The company has stated that the penalty will not have a material impact on its financials, operations, or other activities and is considering filing an appeal with the appellate authority.
Dr. Reddy's Laboratories Limited has received an order from the Joint Commissioner of Customs in Ludhiana, Punjab, imposing a penalty of Rs. 3 crore. The penalty is related to the alleged irregular availing of export incentives by the company under the Customs Act, 1962. The company has stated that the penalty will not have a material impact on its financials, operations, or other activities and is considering filing an appeal with the appellate authority.
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Sept 3 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%.
But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Eli Lilly LLY.N
The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Sept 3 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%.
But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Eli Lilly LLY.N
The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.
Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
Pfizer PFE.N
Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.
It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.
(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)
(([email protected];))
Coya Therapeutics Inc. Secures $4.2 Million Milestone Payment from Dr. Reddy's Laboratories Following FDA Acceptance of ALS Clinical Study IND
Coya Therapeutics Inc. announced on August 29, 2025, that it has received a $4.2 million milestone payment from its strategic partner, Dr. Reddy's Laboratories Ltd., following the U.S. Food and Drug Administration's acceptance of its Investigational New Drug Application. This approval paves the way for Coya to initiate a planned clinical study titled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with an Additional 24-Week Open Label Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)." Additionally, Coya is set to receive another $4.2 million payment upon dosing the first patient in this Phase 2 study.
Coya Therapeutics Inc. announced on August 29, 2025, that it has received a $4.2 million milestone payment from its strategic partner, Dr. Reddy's Laboratories Ltd., following the U.S. Food and Drug Administration's acceptance of its Investigational New Drug Application. This approval paves the way for Coya to initiate a planned clinical study titled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with an Additional 24-Week Open Label Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)." Additionally, Coya is set to receive another $4.2 million payment upon dosing the first patient in this Phase 2 study.
Dr. Reddy's Laboratories Receives Regulatory Approval for Launch of Novel Chronic Constipation Drug, Colozo®, in India
Dr. Reddy's Laboratories Limited has announced the regulatory approval and launch of Linaclotide, marketed under the brand name Colozo®, in India. This approval makes Dr. Reddy's the first pharmaceutical company to introduce Linaclotide, a novel guanylate cyclase-C (GC-C) agonist, for the management of chronic constipation in adults in the country. The medication is available in 72 mcg and 145 mcg strengths and is USFDA-approved for conditions including chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults, as well as functional constipation (FC) in pediatric patients aged 6 to 17 years. This launch signifies a major advancement in Dr. Reddy's gastrointestinal segment portfolio, aiming to address unmet patient needs and enhance quality of life.
Dr. Reddy's Laboratories Limited has announced the regulatory approval and launch of Linaclotide, marketed under the brand name Colozo®, in India. This approval makes Dr. Reddy's the first pharmaceutical company to introduce Linaclotide, a novel guanylate cyclase-C (GC-C) agonist, for the management of chronic constipation in adults in the country. The medication is available in 72 mcg and 145 mcg strengths and is USFDA-approved for conditions including chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults, as well as functional constipation (FC) in pediatric patients aged 6 to 17 years. This launch signifies a major advancement in Dr. Reddy's gastrointestinal segment portfolio, aiming to address unmet patient needs and enhance quality of life.
Dr. Reddy's Laboratories Allocates 4,160 Equity Shares Under Employee Stock Options Plan
Dr. Reddy's Laboratories Limited has announced the allotment of 4,160 equity shares, valued at Re.1/- each, to its employees. These shares have been allocated following the exercise of Stock Options under the company's Employee Stock Options Scheme, initiated in 2002. This move is part of the company's ongoing efforts to provide financial benefits and ownership opportunities to its workforce.
Dr. Reddy's Laboratories Limited has announced the allotment of 4,160 equity shares, valued at Re.1/- each, to its employees. These shares have been allocated following the exercise of Stock Options under the company's Employee Stock Options Scheme, initiated in 2002. This move is part of the company's ongoing efforts to provide financial benefits and ownership opportunities to its workforce.
EMERGING MARKETS-Chilean peso slides on reserve build-up plan; Trump hikes tariffs on Indian goods
Trump imposes additional 25% tariff on India
Brazil's president sees no point in tariff talks with Trump
Oil prices slide to 8-week low as US-Russia talks stir sanction uncertainty
Chile cenbank to accumulate $18.5 bln in international reserves
Updates with afternoon levels
By Ragini Mathur, Johann M Cherian and Sukriti Gupta
Aug 6 (Reuters) - Chile's peso declined the most among Latin American currencies on Wednesday, after the local central bank unveiled plans to boost international reserves, while investors were also scrutinizing U.S. tariffs on India and Brazil.
In a move that surprised investors, U.S. President Donald Trump unveiled an additional tariff on Indian goods , set to take effect 21 days after August 7. The new tariff will push duties on some Indian exports as high as 50% – among the steepest imposed on any U.S. trading partner.
Trump cited New Delhi's continued purchases of Russian oil as the reason for the sharply increased tariff rate.
Indian markets closed before the news, but a U.S.-listed iShares India ETF INDA.N slipped 0.3% to a three-month low. Depository receipts of Dr Reddy's Laboratories RDY.N REDY.NS lost 2.5% and those of Wipro WIT.N WIPR.NS and Infosys INFY.N INFY.NS dipped 1.5% and 0.9%, respectively.
On the currency front, the 1-month rupee forward INR1MNDFOR= was last flat against the dollar.
"While markets have already started pricing in the risk of a sharp tariff hike, a near-term knee-jerk reaction is inevitable — unless there's swift clarity or a breakthrough in negotiations," said Mayuresh Joshi, head of India equity research at William O'Neil.
"India's crude oil imports have remained diversified ... Russia is just one slice of our broader crude basket."
In Latin America, Brazil's real BRL= firmed 0.8% against a weaker dollar and touched a near one-month high and stocks .BVSP gained 1.1% to hit a two-week high as 50% U.S. tariffs on the country's exports took effect.
The U.S. enjoys a trade surplus with Brazil and top export items from the South American country were exempted from the duties last week. The BRICS group of countries has come under greater scrutiny in recent weeks as Trump accused them of pursuing "anti-American policies".
Brazil's President Luiz Inacio Lula da Silva told Reuters in an interview that he saw no room for direct talks with U.S. President Donald Trump, which he believes would turn into a "humiliation" for him.
Meanwhile, Chile's currency fell 0.7% after the country's central bank announced a three-year plan to boost international reserves by $18.5 billion, aiming to strengthen its holdings and reduce dependence on foreign credit lines.
Citigroup moved to "underweight" on the Chilean peso in its EM Bond Portfolio following the reserves program announcement.
Mexico's peso MXN= firmed 0.7% ahead of an interest rate decision by the domestic central bank on Thursday.
Elsewhere, Trump said his special envoy Steve Witkoff had made "great progress" in his meeting with Russian President Vladimir Putin, two days before a deadline set to impose new sanctions if no moves were made to end the conflict with Ukraine.
Crude prices slid to an eight-week low on the sanction uncertainty. The rouble RUB= had closed lower earlier on Wednesday, while international bonds in Ukraine rose broadly.
Key Latin American stock indexes and currencies:
Latin American market prices from Reuters | ||
Equities | Latest | Daily % change |
MSCI Emerging Markets .MSCIEF | 1245.62 | -0.04 |
MSCI LatAm .MILA00000PUS | 2280.98 | 1.30 |
Brazil Bovespa .BVSP | 134637.97 | 1.12 |
Mexico IPC .MXX | 57160.38 | 0.16 |
Chile IPSA .SPIPSA | 8245.78 | 0.62 |
Argentina Merval .MERV | 2414240.13 | 2.9 |
Colombia COLCAP .COLCAP | 1774.53 | 0.72 |
Currencies | Latest | Daily % change |
Brazil real BRL= | 5.4648 | 0.77 |
Mexico peso MXN= | 18.6127 | 0.66 |
Chile peso CLP= | 973.03 | -0.72 |
Colombia peso COP= | 4049.5 | 0.92 |
Peru sol PEN= | 3.554 | - |
Argentina peso (interbank) ARS=RASL | 1331 | 0.6 |
Argentina peso (parallel) ARSB= | 1300 | -0.38 |
(Reporting by Sukriti Gupta, Purvi Agarwal, Ragini Mathur and Johann M Cherian in Bengaluru; Editing by Richard Chang and Mohammed Safi Shamsi)
Trump imposes additional 25% tariff on India
Brazil's president sees no point in tariff talks with Trump
Oil prices slide to 8-week low as US-Russia talks stir sanction uncertainty
Chile cenbank to accumulate $18.5 bln in international reserves
Updates with afternoon levels
By Ragini Mathur, Johann M Cherian and Sukriti Gupta
Aug 6 (Reuters) - Chile's peso declined the most among Latin American currencies on Wednesday, after the local central bank unveiled plans to boost international reserves, while investors were also scrutinizing U.S. tariffs on India and Brazil.
In a move that surprised investors, U.S. President Donald Trump unveiled an additional tariff on Indian goods , set to take effect 21 days after August 7. The new tariff will push duties on some Indian exports as high as 50% – among the steepest imposed on any U.S. trading partner.
Trump cited New Delhi's continued purchases of Russian oil as the reason for the sharply increased tariff rate.
Indian markets closed before the news, but a U.S.-listed iShares India ETF INDA.N slipped 0.3% to a three-month low. Depository receipts of Dr Reddy's Laboratories RDY.N REDY.NS lost 2.5% and those of Wipro WIT.N WIPR.NS and Infosys INFY.N INFY.NS dipped 1.5% and 0.9%, respectively.
On the currency front, the 1-month rupee forward INR1MNDFOR= was last flat against the dollar.
"While markets have already started pricing in the risk of a sharp tariff hike, a near-term knee-jerk reaction is inevitable — unless there's swift clarity or a breakthrough in negotiations," said Mayuresh Joshi, head of India equity research at William O'Neil.
"India's crude oil imports have remained diversified ... Russia is just one slice of our broader crude basket."
In Latin America, Brazil's real BRL= firmed 0.8% against a weaker dollar and touched a near one-month high and stocks .BVSP gained 1.1% to hit a two-week high as 50% U.S. tariffs on the country's exports took effect.
The U.S. enjoys a trade surplus with Brazil and top export items from the South American country were exempted from the duties last week. The BRICS group of countries has come under greater scrutiny in recent weeks as Trump accused them of pursuing "anti-American policies".
Brazil's President Luiz Inacio Lula da Silva told Reuters in an interview that he saw no room for direct talks with U.S. President Donald Trump, which he believes would turn into a "humiliation" for him.
Meanwhile, Chile's currency fell 0.7% after the country's central bank announced a three-year plan to boost international reserves by $18.5 billion, aiming to strengthen its holdings and reduce dependence on foreign credit lines.
Citigroup moved to "underweight" on the Chilean peso in its EM Bond Portfolio following the reserves program announcement.
Mexico's peso MXN= firmed 0.7% ahead of an interest rate decision by the domestic central bank on Thursday.
Elsewhere, Trump said his special envoy Steve Witkoff had made "great progress" in his meeting with Russian President Vladimir Putin, two days before a deadline set to impose new sanctions if no moves were made to end the conflict with Ukraine.
Crude prices slid to an eight-week low on the sanction uncertainty. The rouble RUB= had closed lower earlier on Wednesday, while international bonds in Ukraine rose broadly.
Key Latin American stock indexes and currencies:
Latin American market prices from Reuters | ||
Equities | Latest | Daily % change |
MSCI Emerging Markets .MSCIEF | 1245.62 | -0.04 |
MSCI LatAm .MILA00000PUS | 2280.98 | 1.30 |
Brazil Bovespa .BVSP | 134637.97 | 1.12 |
Mexico IPC .MXX | 57160.38 | 0.16 |
Chile IPSA .SPIPSA | 8245.78 | 0.62 |
Argentina Merval .MERV | 2414240.13 | 2.9 |
Colombia COLCAP .COLCAP | 1774.53 | 0.72 |
Currencies | Latest | Daily % change |
Brazil real BRL= | 5.4648 | 0.77 |
Mexico peso MXN= | 18.6127 | 0.66 |
Chile peso CLP= | 973.03 | -0.72 |
Colombia peso COP= | 4049.5 | 0.92 |
Peru sol PEN= | 3.554 | - |
Argentina peso (interbank) ARS=RASL | 1331 | 0.6 |
Argentina peso (parallel) ARSB= | 1300 | -0.38 |
(Reporting by Sukriti Gupta, Purvi Agarwal, Ragini Mathur and Johann M Cherian in Bengaluru; Editing by Richard Chang and Mohammed Safi Shamsi)
Dr. Reddy's Laboratories Limited Conducted 41st Annual General Meeting
Dr. Reddy's Laboratories Limited held its 41st Annual General Meeting on July 24, 2025, via video conferencing. During the meeting, several proposals were put forward and approved. These included the adoption of financial statements for the fiscal year, the reappointment of auditors, and the ratification of interim dividends. All proposals were passed by the requisite majority.
Dr. Reddy's Laboratories Limited held its 41st Annual General Meeting on July 24, 2025, via video conferencing. During the meeting, several proposals were put forward and approved. These included the adoption of financial statements for the fiscal year, the reappointment of auditors, and the ratification of interim dividends. All proposals were passed by the requisite majority.
Dr. Reddy's Laboratories Reappoints G V Prasad as Co-Chairman and Managing Director for Five-Year Term
Dr. Reddy's Laboratories Limited has announced the re-appointment of Mr. G V Prasad as a Whole-Time Director, Co-Chairman, and Managing Director for a five-year term starting January 30, 2026. This decision was approved by the shareholders during the company's 41st Annual General Meeting held on July 24, 2025.
Dr. Reddy's Laboratories Limited has announced the re-appointment of Mr. G V Prasad as a Whole-Time Director, Co-Chairman, and Managing Director for a five-year term starting January 30, 2026. This decision was approved by the shareholders during the company's 41st Annual General Meeting held on July 24, 2025.
Dr Reddy's kicks off India big pharma earnings with narrow profit miss
Rewrites, adds details, background
July 23 (Reuters) - Indian generic drugs maker Dr Reddy's Laboratories REDY.NS posted a narrow miss of quarterly profit expectations on Wednesday, as it struggled with pricing pressure on drugs and stiff competition in its key North America market.
The firm, one of the top three drugmakers in India by revenue, has been strengthening its consumer healthcare portfolio, which includes over-the-counter medicines, nutrition supplements, as it looks to build a strong pipeline of differentiated products beyond its generics business.
Its total revenue rose 11.4% to 85.72 billion rupees ($992.21 million) in the June quarter, largely helped by an 11% rise in revenue from domestic business.
Revenue from Reddy's biggest market North America fell 11.3% for the quarter.
"The decline was primarily due to increased price erosion in certain key products including Lenalidomide," the company said in a statement.
Lenalidomide, a generic version of Bristol-Myers Squibb's BMY.N popular cancer treatment drug Revlimid, has been a key contributor to the company's North America sales since 2022.
But Revlimid's patent expiry in 2026 would pave way for more number of players in the market, hurting demand for Dr Reddy's products.
Delayed approvals for new drug applications, pricing pressure in the U.S. have been impacting the drugmakers' growth in the market.
Revenue from Europe more than doubled, driven by demand for nicotine replacement therapy, which Dr Reddy's bought from British drugmaker Haleon HLN.L in 2024.
Dr Reddy's consolidated net profit increased to 14.18 billion rupees in the quarter ended June 30, below analysts' estimate of 14.94 billion rupees, as per data compiled by LSEG.
Rival Cipla CIPL.NS is set to report first quarter results on Friday.
($1 = 86.3930 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala)
(([email protected];))
Rewrites, adds details, background
July 23 (Reuters) - Indian generic drugs maker Dr Reddy's Laboratories REDY.NS posted a narrow miss of quarterly profit expectations on Wednesday, as it struggled with pricing pressure on drugs and stiff competition in its key North America market.
The firm, one of the top three drugmakers in India by revenue, has been strengthening its consumer healthcare portfolio, which includes over-the-counter medicines, nutrition supplements, as it looks to build a strong pipeline of differentiated products beyond its generics business.
Its total revenue rose 11.4% to 85.72 billion rupees ($992.21 million) in the June quarter, largely helped by an 11% rise in revenue from domestic business.
Revenue from Reddy's biggest market North America fell 11.3% for the quarter.
"The decline was primarily due to increased price erosion in certain key products including Lenalidomide," the company said in a statement.
Lenalidomide, a generic version of Bristol-Myers Squibb's BMY.N popular cancer treatment drug Revlimid, has been a key contributor to the company's North America sales since 2022.
But Revlimid's patent expiry in 2026 would pave way for more number of players in the market, hurting demand for Dr Reddy's products.
Delayed approvals for new drug applications, pricing pressure in the U.S. have been impacting the drugmakers' growth in the market.
Revenue from Europe more than doubled, driven by demand for nicotine replacement therapy, which Dr Reddy's bought from British drugmaker Haleon HLN.L in 2024.
Dr Reddy's consolidated net profit increased to 14.18 billion rupees in the quarter ended June 30, below analysts' estimate of 14.94 billion rupees, as per data compiled by LSEG.
Rival Cipla CIPL.NS is set to report first quarter results on Friday.
($1 = 86.3930 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala)
(([email protected];))
Dr Reddy's Laboratories Ltd expected to post earnings of ₹18.00 a share - Earnings Preview
Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on July 23 for the period ending June 30 2025
The Hyderabad Telangana-based company is expected to report a 14.6% increase in revenue to ₹88.234 billion from ₹76.96 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹18.00 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $16.37, about 11.5% above its last closing price of $14.48
This summary was machine generated July 21 at 11:01 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])
Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on July 23 for the period ending June 30 2025
The Hyderabad Telangana-based company is expected to report a 14.6% increase in revenue to ₹88.234 billion from ₹76.96 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹18.00 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $16.37, about 11.5% above its last closing price of $14.48
This summary was machine generated July 21 at 11:01 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])
Dr Reddy's Laboratories Says USFDA Completes Inspection At co's Srikakulam Facility
July 18 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
DR REDDY'S LABORATORIES LTD - USFDA COMPLETES INSPECTION AT DR. REDDY'S SRIKAKULAM FACILITY
DR REDDY'S LABORATORIES LTD - ISSUED FORM 483 WITH 7 OBSERVATIONS BY USFDA
Source text: ID:nBSE6WH7dN
Further company coverage: REDY.NS
(([email protected];))
July 18 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
DR REDDY'S LABORATORIES LTD - USFDA COMPLETES INSPECTION AT DR. REDDY'S SRIKAKULAM FACILITY
DR REDDY'S LABORATORIES LTD - ISSUED FORM 483 WITH 7 OBSERVATIONS BY USFDA
Source text: ID:nBSE6WH7dN
Further company coverage: REDY.NS
(([email protected];))
Dr. Reddy's Laboratories Limited Publishes Annual Report for FY 2025
Dr. Reddy's Laboratories Limited has published its annual report for the fiscal year 2025, providing a comprehensive overview of its business operations and financial performance. The report outlines the company's employee stock option schemes, including the DR. REDDY'S EMPLOYEES STOCK OPTION SCHEME, 2018, and highlights there have been no material changes in these schemes. It confirms compliance with relevant regulations. Furthermore, the report notes the appointment of M.V. Narasimham as the Chief Financial Officer effective August 1, 2024. Dr. Reddy's Laboratories continues to demonstrate its commitment to transparency and adherence to regulatory requirements. The full report can be accessed through the link below.
Dr. Reddy's Laboratories Limited has published its annual report for the fiscal year 2025, providing a comprehensive overview of its business operations and financial performance. The report outlines the company's employee stock option schemes, including the DR. REDDY'S EMPLOYEES STOCK OPTION SCHEME, 2018, and highlights there have been no material changes in these schemes. It confirms compliance with relevant regulations. Furthermore, the report notes the appointment of M.V. Narasimham as the Chief Financial Officer effective August 1, 2024. Dr. Reddy's Laboratories continues to demonstrate its commitment to transparency and adherence to regulatory requirements. The full report can be accessed through the link below.
Dr. Reddy's Laboratories Limited Publishes ESG Reporting Criteria for 2024-25
Dr. Reddy's Laboratories Limited has published the ESG Reporting Criteria for FY 2024-25, detailing the methodology, assumptions, and exclusions for measuring progress on ESG targets. The report includes metrics such as patients reached through the Sparsh patient support program and the percentage of new product launches that are first to market in a given country. The full report can be accessed through the link below.
Dr. Reddy's Laboratories Limited has published the ESG Reporting Criteria for FY 2024-25, detailing the methodology, assumptions, and exclusions for measuring progress on ESG targets. The report includes metrics such as patients reached through the Sparsh patient support program and the percentage of new product launches that are first to market in a given country. The full report can be accessed through the link below.
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
Dr. Reddy's Laboratories Announces Allotment of 10,685 Equity Shares to Employees Under Stock Options Plan
Dr. Reddy's Laboratories Limited has announced the allotment of 10,685 equity shares, each valued at Re.1, to eligible employees following the exercise of Stock Options. This allocation, which took place on June 23, 2025, is part of the company's Employees Stock Options Scheme, 2002, and the Employees ADR Stock Options Scheme, 2007. The move is in compliance with the SEBI regulations regarding Share Based Employee Benefits.
Dr. Reddy's Laboratories Limited has announced the allotment of 10,685 equity shares, each valued at Re.1, to eligible employees following the exercise of Stock Options. This allocation, which took place on June 23, 2025, is part of the company's Employees Stock Options Scheme, 2002, and the Employees ADR Stock Options Scheme, 2007. The move is in compliance with the SEBI regulations regarding Share Based Employee Benefits.
Dr. Reddy's Laboratories Announces Allotment of 57,885 Equity Shares Under Employee Stock Options Plan
Dr. Reddy's Laboratories Limited has announced the allotment of 57,885 fully paid-up equity shares, each valued at Re.1/-, to eligible employees. This allocation follows the exercise of Stock Options under the company's Employees Stock Options Scheme, 2002, and the Employees ADR Stock Options Scheme, 2007. The allotment, completed on June 14, 2025, is part of the company's ongoing employee compensation plans. Further details were provided in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Dr. Reddy's Laboratories Limited has announced the allotment of 57,885 fully paid-up equity shares, each valued at Re.1/-, to eligible employees. This allocation follows the exercise of Stock Options under the company's Employees Stock Options Scheme, 2002, and the Employees ADR Stock Options Scheme, 2007. The allotment, completed on June 14, 2025, is part of the company's ongoing employee compensation plans. Further details were provided in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Alvotech SA and Dr. Reddy's Laboratories Announce Partnership to Co-Develop Biosimilar to Keytruda®
Alvotech SA has announced a new collaboration with Dr. Reddy's Laboratories Ltd. to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab), a widely used cancer treatment. This partnership will leverage the strengths of both companies in biosimilar development, aiming to expedite the process and expand global access to this critical medication. Both companies will share responsibilities and costs associated with the development and manufacturing of the biosimilar. The agreement marks a significant step in providing cost-effective biologic treatments to patients worldwide, particularly in the field of oncology, which is a focus area for Dr. Reddy's. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Alvotech SA has announced a new collaboration with Dr. Reddy's Laboratories Ltd. to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab), a widely used cancer treatment. This partnership will leverage the strengths of both companies in biosimilar development, aiming to expedite the process and expand global access to this critical medication. Both companies will share responsibilities and costs associated with the development and manufacturing of the biosimilar. The agreement marks a significant step in providing cost-effective biologic treatments to patients worldwide, particularly in the field of oncology, which is a focus area for Dr. Reddy's. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Dr. Reddy's Laboratories Reports 16.6% Increase in Revenues to Rs. 325,535 Million for Fiscal Year Ending March 2025
Dr. Reddy's Laboratories Limited reported its financial results for the fiscal year ending March 31, 2025, showing a notable increase in revenues. The company's revenues reached Rs. 325.5 billion ($3.81 billion), marking a substantial rise from Rs. 279.2 billion in the previous year. This growth is primarily driven by the Global Generics segment, which saw revenues increase by 18% to Rs. 289.6 billion, compared to Rs. 245.5 billion in the prior year. This improvement was attributed to a 14% net increase in sales volumes across all business geographies, including North America, Europe, Emerging Markets, and India. The cost of revenues for the year was Rs. 135.1 billion, up from Rs. 115.6 billion the previous year. Gross profit was recorded at Rs. 190.4 billion, reflecting an increase from Rs. 163.6 billion in the fiscal year 2024. The company continues to focus on expanding access to affordable and innovative medicines globally, as evidenced by the revenue growth across its major markets. No specific outlook or guidance for the upcoming fiscal year was provided in the report.
Dr. Reddy's Laboratories Limited reported its financial results for the fiscal year ending March 31, 2025, showing a notable increase in revenues. The company's revenues reached Rs. 325.5 billion ($3.81 billion), marking a substantial rise from Rs. 279.2 billion in the previous year. This growth is primarily driven by the Global Generics segment, which saw revenues increase by 18% to Rs. 289.6 billion, compared to Rs. 245.5 billion in the prior year. This improvement was attributed to a 14% net increase in sales volumes across all business geographies, including North America, Europe, Emerging Markets, and India. The cost of revenues for the year was Rs. 135.1 billion, up from Rs. 115.6 billion the previous year. Gross profit was recorded at Rs. 190.4 billion, reflecting an increase from Rs. 163.6 billion in the fiscal year 2024. The company continues to focus on expanding access to affordable and innovative medicines globally, as evidenced by the revenue growth across its major markets. No specific outlook or guidance for the upcoming fiscal year was provided in the report.
Dr Reddy's Laboratories Says LIC Shareholding In Dr. Reddy's Laboratories Increases To 8.216%
June 5 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
LIC SHAREHOLDING IN DR. REDDY'S LABORATORIES INCREASES TO 8.216%
Source text: ID:nBSE347R25
Further company coverage: REDY.NS
(([email protected];;))
June 5 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:
LIC SHAREHOLDING IN DR. REDDY'S LABORATORIES INCREASES TO 8.216%
Source text: ID:nBSE347R25
Further company coverage: REDY.NS
(([email protected];;))
Dr. Reddy's Faces Tax Reassessment Notice Over Merger; No Material Impact Expected
Dr. Reddy's Laboratories Limited has announced a tax-related issue concerning the reassessment of their financial statements for the Assessment Year 2020-21. The Office of the Assistant Commissioner of Income Tax, circle 8(1), Hyderabad, issued a notice under Section 148A of the Indian Income Tax Act, 1961, questioning the company's tax returns following the merger of Dr. Reddy's Holding Limited into Dr. Reddy's Laboratories Limited, a move approved by the National Company Law Tribunal in 2022. An order received on May 30, 2025, necessitates further reassessment of the income for the specified year. The company, however, maintains that there is no tax escapement due to the merger and asserts that the outcome will not materially impact their financials or operations. A proposed demand of approximately Rs. 2,395.82 crore has been quantified, but the company is currently reviewing the notice and plans to respond as necessary. The scheme of amalgamation ensures that promoters will indemnify the company against any liabilities arising from the merger.
Dr. Reddy's Laboratories Limited has announced a tax-related issue concerning the reassessment of their financial statements for the Assessment Year 2020-21. The Office of the Assistant Commissioner of Income Tax, circle 8(1), Hyderabad, issued a notice under Section 148A of the Indian Income Tax Act, 1961, questioning the company's tax returns following the merger of Dr. Reddy's Holding Limited into Dr. Reddy's Laboratories Limited, a move approved by the National Company Law Tribunal in 2022. An order received on May 30, 2025, necessitates further reassessment of the income for the specified year. The company, however, maintains that there is no tax escapement due to the merger and asserts that the outcome will not materially impact their financials or operations. A proposed demand of approximately Rs. 2,395.82 crore has been quantified, but the company is currently reviewing the notice and plans to respond as necessary. The scheme of amalgamation ensures that promoters will indemnify the company against any liabilities arising from the merger.
Dr. Reddy's Laboratories Faces USFDA Observations After Inspection at Telangana Facility
Dr. Reddy's Laboratories Limited has announced that the United States Food & Drug Administration (USFDA) recently completed a Good Manufacturing Practice (GMP) inspection at their Active Pharmaceutical Ingredient (API) manufacturing facility in Miryalaguda, Telangana, India. The inspection, which took place from May 19 to May 24, 2025, resulted in the issuance of a Form 483 with two observations. The company has stated that they will address these observations within the stipulated timeline.
Dr. Reddy's Laboratories Limited has announced that the United States Food & Drug Administration (USFDA) recently completed a Good Manufacturing Practice (GMP) inspection at their Active Pharmaceutical Ingredient (API) manufacturing facility in Miryalaguda, Telangana, India. The inspection, which took place from May 19 to May 24, 2025, resulted in the issuance of a Form 483 with two observations. The company has stated that they will address these observations within the stipulated timeline.
Upcoming Events:
Quarterly Results
Events:
Dividend
Split
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Large Cap Ideas
See similar 'Large' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Dr. Reddy's Lab do?
Dr. Reddy’s Laboratories is a multinational pharmaceutical company that manufactures and markets a wide range of pharmaceutical products and services. Through its businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Who are the competitors of Dr. Reddy's Lab?
Dr. Reddy's Lab major competitors are Mankind Pharma, Zydus Lifesciences, Torrent Pharma, Cipla, Lupin, Alkem Laboratories, Abbott India. Market Cap of Dr. Reddy's Lab is ₹1,04,556 Crs. While the median market cap of its peers are ₹98,213 Crs.
Is Dr. Reddy's Lab financially stable compared to its competitors?
Dr. Reddy's Lab seems to be less financially stable compared to its competitors. Altman Z score of Dr. Reddy's Lab is 6.83 and is ranked 7 out of its 8 competitors.
Does Dr. Reddy's Lab pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Dr. Reddy's Lab latest dividend payout ratio is 11.8% and 3yr average dividend payout ratio is 12.85%
How has Dr. Reddy's Lab allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Dr. Reddy's Lab balance sheet?
Balance sheet of Dr. Reddy's Lab is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Dr. Reddy's Lab improving?
Yes, profit is increasing. The profit of Dr. Reddy's Lab is ₹5,727 Crs for TTM, ₹5,655 Crs for Mar 2025 and ₹5,578 Crs for Mar 2024.
Is the debt of Dr. Reddy's Lab increasing or decreasing?
Yes, The net debt of Dr. Reddy's Lab is increasing. Latest net debt of Dr. Reddy's Lab is -₹243.7 Crs as of Mar-25. This is greater than Mar-24 when it was -₹1,453.3 Crs.
Is Dr. Reddy's Lab stock expensive?
Dr. Reddy's Lab is not expensive. Latest PE of Dr. Reddy's Lab is 18.41, while 3 year average PE is 25.3. Also latest EV/EBITDA of Dr. Reddy's Lab is 12.53 while 3yr average is 15.6.
Has the share price of Dr. Reddy's Lab grown faster than its competition?
Dr. Reddy's Lab has given lower returns compared to its competitors. Dr. Reddy's Lab has grown at ~6.77% over the last 2yrs while peers have grown at a median rate of 23.55%
Is the promoter bullish about Dr. Reddy's Lab?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Dr. Reddy's Lab is 26.64% and last quarter promoter holding is 26.64%.
Are mutual funds buying/selling Dr. Reddy's Lab?
The mutual fund holding of Dr. Reddy's Lab is increasing. The current mutual fund holding in Dr. Reddy's Lab is 13.61% while previous quarter holding is 12.89%.